Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model.

Anti-TNF therapy Crohn’s disease Disease course Immunosuppressive therapy Predictors

Journal

International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899

Informations de publication

Date de publication:
Oct 2019
Historique:
accepted: 16 08 2019
pubmed: 26 8 2019
medline: 6 2 2020
entrez: 26 8 2019
Statut: ppublish

Résumé

The aim of our study was to identify clinical parameters in recently diagnosed Crohn's disease (CD) patients for prediction of their disease course. EPIC (Early Predictive parameters of Immunosuppressive therapy in Crohn's disease) is a prospective, observational study in 341 patients with a recent CD diagnosis (≤ 6 months), and naïve to immunosuppressants (IS) and anti-tumor necrosis factor α (TNF) agents. Patient characteristics were documented up to 2 years. In line with national and international guidelines, a complicated disease course was defined as need for immunosuppressants and/or anti-TNF agents, and CD-related hospitalization with or without immunosuppressants and/or anti-TNF agents. A total of 212 CD patients were analyzed of whom 57 (27%) had an uncomplicated disease within 24 months, while 155 (73%) had a complicated disease course: need for IS and/or anti-TNF agents (N = 115), CD-related hospitalization with or without IS/anti-TNF agents (N = 40). Identified risk predictors for a complicated disease were as follows: age at onset < 40 years (OR 2.3; 95% CI 1.2-4.5), anemia (OR 2.1; 95% CI 1.1-4.2), and treatment with systemic corticosteroids at first flare (OR 2.2; 95% CI 1.1-4.7). These three parameters were used to develop a risk model allowing prediction of the future disease course. Our three-parameter model enables an assessment of each CD patient's risk to develop a complicated disease course. Due to the easy accessibility of these parameters, this model can be utilized in daily clinical care to assist selecting the initial treatment for each individual patient.

Identifiants

pubmed: 31446480
doi: 10.1007/s00384-019-03369-0
pii: 10.1007/s00384-019-03369-0
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1653-1660

Subventions

Organisme : AbbVie Deutschland
ID : unknown

Références

Inflamm Bowel Dis. 2002 Jul;8(4):244-50
pubmed: 12131607
Gastroenterology. 2004 Feb;126(2):414-24
pubmed: 14762777
Gut. 2006 Aug;55(8):1124-30
pubmed: 16361306
Gastroenterology. 2006 Mar;130(3):650-6
pubmed: 16530505
Inflamm Bowel Dis. 2007 Apr;13(4):481-9
pubmed: 17206705
Scand J Gastroenterol. 2007 May;42(5):602-10
pubmed: 17454881
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1430-8
pubmed: 18054751
Lancet. 2008 Feb 23;371(9613):660-667
pubmed: 18295023
Gut. 2009 Mar;58(3):388-95
pubmed: 18824555
Gastroenterology. 2008 Nov;135(5):1442-7
pubmed: 18848556
Scand J Gastroenterol. 2008 Aug;43(8):948-54
pubmed: 19086165
Am J Gastroenterol. 2008 Dec;103(12):3082-93
pubmed: 19086959
Am J Gastroenterol. 2009 Feb;104(2):371-83
pubmed: 19174787
Gastroenterology. 2010 Oct;139(4):1147-55
pubmed: 20637205
Gut. 2010 Sep;59(9):1200-6
pubmed: 20650924
J Dig Dis. 2011 Apr;12(2):99-104
pubmed: 21401894
Inflamm Bowel Dis. 2012 Sep;18(9):1647-54
pubmed: 22081542
J Crohns Colitis. 2012 Feb;6(1):21-8
pubmed: 22261524
J Crohns Colitis. 2013 Aug;7(7):e263-70
pubmed: 23182164
J Gastroenterol Hepatol. 2014 Jan;29(1):74-82
pubmed: 23981141
Curr Gastroenterol Rep. 2014 Nov;16(11):416
pubmed: 25262067
Z Gastroenterol. 2014 Dec;52(12):1431-84
pubmed: 25474283
J Gastroenterol Hepatol. 2015 Sep;30(9):1346-53
pubmed: 25867770
J Crohns Colitis. 2016 Dec;10(12):1385-1394
pubmed: 27282402
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341

Auteurs

Andreas Stallmach (A)

Clinic for Internal Medicine IV, Jena University Hospital, Jena, Germany. andreas.stallmach@med.uni-jena.de.

Bernd Bokemeyer (B)

Gastroenterology Practice, Minden, Germany.

Ulf Helwig (U)

Internistische Praxisgemeinschaft Oldenburg, Oldenburg, Germany.

Andreas Lügering (A)

MVZ Portal 10, Münster, Germany.

Niels Teich (N)

Internistische Gemeinschaftspraxis, Leipzig, Germany.
Medical Faculty, Jena University Hospital, Jena, Germany.

Imma Fischer (I)

Biostatistik Tübingen, Tübingen, Germany.

Stefan Rath (S)

Medical Department, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.

Dorothee Lang (D)

Medical Department, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.

Carsten Schmidt (C)

Clinic for Internal Medicine IV, Jena University Hospital, Jena, Germany.
Medical Clinic II, Fulda Hospital AG, Fulda, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH